Literature DB >> 16988764

Dynamics of immature subsets of dendritic cells during antiviral therapy in HLA-A24-positive chronic hepatitis C patients.

Masaaki Shiina1, Koju Kobayashi, Tomoo Kobayashi, Yasuteru Kondo, Yoshiyuki Ueno, Tooru Shimosegawa.   

Abstract

BACKGROUND: The cellular immune response is important in chronic hepatitis C (CHC). To better understand its mechanism, we examined dendritic cells (DCs) and hepatitis C virus (HCV)-specific cytotoxic T cells (CTLs), which are thought to contribute to liver injury and viral clearance.
METHODS: CHC patients received 24 weeks of interferon-alpha-based antiviral therapy. We analyzed time-sequential frequencies of peripheral DCs, classified as myeloid DCs (mDCs) or plasmacytoid DCs (pDCs), together with peptide major histocompatibility class I tetramers, epitope specific for HCV core 129-137 (t*24/c129) or HCV NS3 1296-1304 (t*24/ns1294), directly ex vivo.
RESULTS: The mDC and pDC populations changed in parallel (P < 0.05), showing a significant transient decrease at weeks 12 and 16 during the therapy, and then recovering. However, neither of the tetramer results showed a direct correlation with the kinetics of peripheral DCs.
CONCLUSIONS: There is an apparent effect of antiviral therapy or a subsequent reduction of HCV on host immunity, but the effect may not include the induction of CTLs in CHC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988764     DOI: 10.1007/s00535-006-1843-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  40 in total

Review 1.  SYFPEITHI: database for MHC ligands and peptide motifs.

Authors:  H Rammensee; J Bachmann; N P Emmerich; O A Bachor; S Stevanović
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

Review 2.  The host type I interferon response to viral and bacterial infections.

Authors:  Andrea K Perry; Gang Chen; Dahai Zheng; Hong Tang; Genhong Cheng
Journal:  Cell Res       Date:  2005-06       Impact factor: 25.617

3.  Type I interferon production is profoundly and transiently impaired in primary HIV-1 infection.

Authors:  Isabelle Kamga; Sandrine Kahi; Leyla Develioglu; Miriam Lichtner; Concepción Marañón; Christiane Deveau; Laurence Meyer; Cécile Goujard; Pierre Lebon; Martine Sinet; Anne Hosmalin
Journal:  J Infect Dis       Date:  2005-06-15       Impact factor: 5.226

4.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

Review 5.  Hepatitis C and hepatocellular carcinoma.

Authors:  A M Di Bisceglie
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

Review 6.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

7.  Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection.

Authors:  Tatsuya Kanto; Michiyo Inoue; Hideki Miyatake; Aki Sato; Mitsuru Sakakibara; Takayuki Yakushijin; Chika Oki; Ichiyo Itose; Naoki Hiramatsu; Tetsuo Takehara; Akinori Kasahara; Norio Hayashi
Journal:  J Infect Dis       Date:  2004-10-27       Impact factor: 5.226

8.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

9.  Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.

Authors:  B Rehermann; K M Chang; J McHutchinson; R Kokka; M Houghton; C M Rice; F V Chisari
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus.

Authors:  Randy S Longman; Andrew H Talal; Ira M Jacobson; Matthew L Albert; Charles M Rice
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

View more
  5 in total

1.  Do DCs influence the antiviral effect of interferon/ribavirin by changing their profile during the therapy?

Authors:  Hiroki Takahashi; Mikio Zeniya
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

2.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

3.  Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-alpha in patients with chronic hepatitis C.

Authors:  Ivo Ivić; Nikola Bradarić; Neira Puizina-Ivić; Dragan Ledina; Boris Luksić; Roko Martinić
Journal:  Croat Med J       Date:  2007-12       Impact factor: 1.351

Review 4.  Dendritic cells in hepatitis C infection: can they (help) win the battle?

Authors:  Angela Dolganiuc; Gyongyi Szabo
Journal:  J Gastroenterol       Date:  2011-02-17       Impact factor: 6.772

Review 5.  Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells.

Authors:  Deepa Rana; Yogesh Chawla; Sunil K Arora
Journal:  Indian J Med Res       Date:  2013-11       Impact factor: 2.375

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.